



Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference

September 2, 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Sep. 2, 2026-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and *in vivo* CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference being held from September 14-16, 2026, in New York.

Details of the event are as follows:

Date: Tuesday, September 15, 2026

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio's website at <https://www.adicetbio.com>. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing a broad pipeline of allogeneic gamma delta T cell therapies, engineered with chimeric antigen receptors (CARs), alongside differentiated *in vivo* CAR-T therapies with the potential to redefine treatment across autoimmune diseases, hematologic malignancies and solid tumors. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260902301741/en/>

Adicet Bio, Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Penelope Belnap

Precision AQ

Penelope.belnap@precisionaq.com

Source: Adicet Bio, Inc.